Abstract
Background: For type II diabetes (T2D) subjects to better regulate carbohydrate consumption and manage blood glucose levels, a non-nutritive sweetener (aspartame) is prescribed as an alternative to natural sugar. Previous studies show that there was a 68% rise in the probability of aspartame consumers developing T2D compared with non-consumers. In diabetes and inflammation, deformed red blood cells (RBCs) and atypical fibrin fibre formation or an altered fibrin structure are especially prevalent.
Objective: The aim of this study was to investigate, in subjects with T2D taking aspartame, clot viscoelasticity and platelet structure.
Methodology: Blood was drawn from 12 T2D subjects from the diabetic clinic at the Steve Biko Academic Hospital, South Africa. Blood was used to perform a full blood count, thromboelastography (TEG) and scanning electron microscopy (SEM).
Results: SEM showed increased platelet activation and abnormal TEG parameters in T2D consuming aspartame.
Conclusion: A hypercoagulable state can increase the risk of thromboembolic complications and an increased incidence of vascular disease. This knowledge may be used to build awareness among consumers of aspartame.
Publisher
European Open Science Publishing
Reference47 articles.
1. Roberts HJ. Reactions attributed to aspartame-containing products: 551 cases. J Appl Nutr. 1988; 40: 85-94.
2. Stegink LD, Filer LJ Jr, Bell EF, Ziegler EE, Tephly TR. Effect of repeated ingestion of aspartame-sweetened beverage on plasma amino acid, blood methanol, and blood formate concentrations in normal adults. Metabolism. 1989; 38:357-63.
3. Butchko HH, Stargel WW. Aspartame: scientific evaluation in the postmarketing period. Regul Toxicol Pharmacol. 2001; 34:221-33.
4. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care. 2006; 29 Suppl 1:S4-42.
5. Gougeon R, Spidel M, Lee K, Field CJ: Canadian Diabetes Association National Nutrition Committee Technical Review: Non-nutritive intense sweeteners in diabetes management. Can J Diabetes, 2004; 28: 385-399.